Progressive supranuclear palsy: Advances in diagnosis and management
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Progressive supranuclear palsy (PSP) is a complex clinicopathologic disease with no current cure or disease modulating therapies that can only be definitively confirmed at autopsy. Growing understanding of the phenotypic diversity of PSP has led to expanded clinical criteria and new insights into etiopathogenesis that coupled with improved in vivo biomarkers makes increased access to current clinical trials possible. Current standard-of-care treatment of PSP is multidisciplinary, supportive and symptomatic, and several trials of potentially disease modulating agents have already been completed with disappointing results. Current ongoing clinical trials target the abnormal aggregation of tau through a variety of mechanisms including immunotherapy and gene therapy offer a more direct method of treatment. Here we review PSP clinicopathologic correlations, in vivo biomarkers including MRI, PET, and CSF biomarkers. We additionally review current pharmacologic and non-pharmacologic methods of treatment, prior and ongoing clinical trials in PSP. Newly expanded clinical criteria and improved specific biomarkers will aid in identifying patients with PSP earlier and more accurately and expand access to these potentially beneficial clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · cited 4×
“NINDS-SPSP criteria) which outlined the core clinical features of what is currently known as the PSP-Richardson syndrome (PSP-RS) of a gradual progressive disorder affecting patients over 40 years old with a vertical supranuclear gaze palsy or postural instability and falls within the first year of onset [27].”
BackgroundMethodInfluentialSelf-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
Harding, H. P., Zhang, Y., Bertolotti, A., Zeng, H., & Ron, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80330-5 · Cited by 2,021
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“CSF neurofilament light chain (NfL), an intermediate filament and non-specific measure of neuronal injury [135], shows elevation in PSP and other atypical parkinsonian syndromes [132, 136–139].”
BackgroundTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Several tau directed passive immunotherapy trials in Alzheimer’s disease have been performed with limited success (for a recent review see [220]).”
BackgroundDistinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986 · cited 2×
“In vivo animal studies using preformed fibrils [97, 98], human diseased brain homogenates [99], and other techniques [100, 101] have shown distal spread of tau pathology via trans-synaptic spread [102, 103].”
BackgroundTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 1×
“As stated previously, in PSP the accumulated tau is mostly of a 4R variety and is typically phosphorylated [53, 54], often acetylated [55], and thioflavin-S positive [56].”
BackgroundGoedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929 · cited 1×
“Due to alternative splicing of the of microtubule binding site domains E2, E3, and E10, six tau isoforms exist, either with 4 repeated domains (4R, which includes the E10 region), or 3 repeated domains (3R, which excludes E10) [3].”
BackgroundAssociation of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781 · cited 1×
“6 times the risk for developing PSP, which is comparable to the ApoE ε3/ε4 risk for developing Alzheimer disease [19, 71].”
ResultSelf-citationKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2642-12.2013 · Cited by 664
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
PSP Genetics Study Group, Höglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M. A., Wang, L.-S., Klei, L., Rademakers, R., de Silva, R., Litvan, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.859 · Cited by 603
Self-citationTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594
Isolated bipallidal lesions caused by extrapontine myelinolysis.
(2008) · Institutional Research Information System (Università degli Studi di Brescia) · doi:10.1212/01 · Cited by 573
Trans-cellular Propagation of Tau Aggregation by Fibrillar Species
Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552 · cited 1×
“These aggregations may be transported within the cellular structure and be transferred from cell to cell in a variety of mechanisms [212, 213].”
BackgroundInhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516 · cited 1×
“Salsalate inhibits tau acetylation which may alleviate tau pathology as well [199] and is undergoing a phase I pilot study in PSP (NCT02422485).”
BackgroundAsuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R., & Kayed, R. (2012) · Scientific Reports · doi:10.1038/srep00700 · Cited by 502
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 1×
“Positron Emission Tomography—Several tracers are under development that bind to the tau protein including 18F-5105, 18F-FDDNP, 18F-THK523, 11C-PBB3, and others [118].”
BackgroundAn autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · cited 1×
“However, retention appears to be less robust in 4R tauopathies [119, 124, 125].”
BackgroundHall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473
Guo, J. L., Narasimhan, S., Changolkar, L., He, Z., Stieber, A., Zhang, B., Gathagan, R. J., Iba, M., McBride, J. D., Trojanowski, J. Q., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160833 · Cited by 440
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401 · cited 1×
“A separate compound, epothilone D, which also stabilizes microtubules may be of interest, but is still early in development [208].”
BackgroundDoes corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
Neuropathology of variants of progressive supranuclear palsy
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833be924 · Cited by 386 · cited 1×
“cortically localizing clinical signs have been described to have higher burdens of corresponding cortical tau pathology [58, 59] (figure 2).”
BackgroundNeuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)
Dickson, D. W., Kouri, N., Murray, M. E., & Josephs, K. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9589-0 · Cited by 380
Macromolecular permeability across the blood-nerve and blood-brain barriers.
Poduslo, J. F., Curran, G. L., & Berg, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5705 · Cited by 377
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Self-citationBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 1×
“Selecting the right epitope target may be challenging as antibodies can be raised to target different regions of tau [227, 228], tau species with specific posttranslational modifications [229, 230], or oligomers or specific conformations [120, 228, Coughlin and Litvan Page 9”
BackgroundBoxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · cited 1×
“Microtubule-stabilizing agents—A neuropeptide with neuroprotective and microtubule stabilizing properties, davunetide, which looked promising in animal models [204] was studied in a multicenter phase IIb/III trial of over 300 patients with PSP but regrettably failed to show clinical efficacy on all endpoints [205].”
BackgroundSelf-citationAcetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Brain · doi:10.1093/brain/aws013 · Cited by 281 · cited 1×
“As stated previously, in PSP the accumulated tau is mostly of a 4R variety and is typically phosphorylated [53, 54], often acetylated [55], and thioflavin-S positive [56].”
BackgroundTheunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
Corticobasal degeneration: a pathologically distinct 4R tauopathy
Kouri, N., Whitwell, J. L., Josephs, K. A., Rademakers, R., & Dickson, D. W. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.43 · Cited by 246 · cited 1×
“While PSP and CBD are both 4R tauopathies, the pathological features of PSP are typically tufted astrocytes and globose neurofibrillary tangles, whereas CBD has astrocytic plaques and ballooned pale neurons with thready neuronal tau inclusions that affect cortical regions more severely than subcortical regions and in…”
BackgroundKouri, N., Ross, O. A., Dombroski, B., Younkin, C. S., Serie, D. J., Soto-Ortolaza, A., Baker, M., Finch, N. C. A., Yoon, H., Kim, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8247 · Cited by 239
Self-citationSmoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., & Gouaux, B. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110837 · Cited by 235
Voxel-based morphometry in autopsy proven PSP and CBD
Josephs, K. A., Whitwell, J. L., Dickson, D. W., Boeve, B. F., Knopman, D. S., Petersen, R. C., Parisi, J. E., & Jack, C. R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.019 · Cited by 234 · cited 1×
“Frontal, temporal, and parietal cortices may also show disease [57] and patients who exhibit more Coughlin and Litvan Page 3”
BackgroundHuman secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230
Peeraer, E., Bottelbergs, A., Van Kolen, K., Stancu, I.-C., Vasconcelos, B., Mahieu, M., Duytschaever, H., Ver Donck, L., Torremans, A., Sluydts, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.032 · Cited by 214 · cited 1×
“Tau Immunotherapy—Recent in vitro and in vivo experiments have shown that abnormally folded proteins may be capable of inducing misfolding in normal native proteins and creating spread of pathology through ‘prion-like’ templating [99, 103, 209, 210].”
BackgroundLoss of O -GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration
Wang, A. C., Jensen, E. H., Rexach, J. E., Vinters, H. V., & Hsieh-Wilson, L. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606899113 · Cited by 211
Ishizawa, K., & Dickson, D. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.6.647 · Cited by 209 · cited 1×
“Other studies have reported that microglial activation correlates with tau deposition [89] and higher levels of pro-inflammatory cytokines can be demonstrated in the CSF of PSP patients when compared to Parkinson’s disease patients [90].”
ResultPlasma neurofilament light chain predicts progression in progressive supranuclear palsy
Rojas, J. C., Karydas, A., Bang, J., Tsai, R. M., Blennow, K., Liman, V., Kramer, J. H., Rosen, H., Miller, B. L., Zetterberg, H., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.290 · Cited by 206
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Schoch, K. M., DeVos, S. L., Miller, R. L., Chun, S. J., Norrbom, M., Wozniak, D. F., Dawson, H. N., Bennett, C. F., Rigo, F., & Miller, T. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.042 · Cited by 175
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174
In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
Gerhard, A., Trender‐Gerhard, I., Turkheimer, F., Quinn, N. P., Bhatia, K. P., & Brooks, D. J. (2006) · Movement Disorders · doi:10.1002/mds.20668 · Cited by 171 · cited 2×
“Activated microglia can be visualized using positron emission tomography in PSP which will be discussed below [92].”
BackgroundMethodAntisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161 · cited 3×
“These areas are not typically affected by tau pathology in PSP as are the frontal lobes, basal ganglia, or brainstem structures [197, 198].”
Background[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159
Serum NFL discriminates Parkinson disease from atypical parkinsonisms
Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., Otto, M., & Verbeek, M. M. (2019) · Neurology · doi:10.1212/wnl.0000000000007179 · Cited by 153
Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153
Motor and cognitive deficits in aged tau knockout mice in two background strains
Lei, P., Ayton, S., Moon, S., Zhang, Q., Volitakis, I., Finkelstein, D. I., & Bush, A. I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-29 · Cited by 145
Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease
Kraus, A., Saijo, E., Metrick, M. A., Newell, K., Sigurdson, C. J., Zanusso, G., Ghetti, B., & Caughey, B. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1947-3 · Cited by 143 · cited 1×
“RT-QuIC are very promising in the diagnosis of synucleinopathies (Parkinson’s disease, dementia with Lewy bodies, multiple systems atrophy) [143–145] and is also expanding into tauopathies including PSP [146, 147].”
BackgroundCognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion
Ahmed, T., Van der Jeugd, A., Blum, D., Galas, M.-C., D’Hooge, R., Buee, L., & Balschun, D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.005 · Cited by 137
Tau filaments in neurodegenerative diseases
Goedert, M. (2018) · FEBS Letters · doi:10.1002/1873-3468.13108 · Cited by 127
Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy
Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2017) · Movement Disorders · doi:10.1002/mds.26844 · Cited by 119
Increased basal ganglia binding of 18F‐AV‐1451 in patients with progressive supranuclear palsy
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26813 · Cited by 118
International FTD-Genomics Consortium (IFGC), Yokoyama, J. S., Karch, C. M., Fan, C. C., Bonham, L. W., Kouri, N., Ross, O. A., Rademakers, R., Kim, J., Wang, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1693-y · Cited by 112 · cited 1×
“MOBP, which encodes for myelin basic protein, is also implicated in CBD and highlights to potential importance of white matter in these conditions [74].”
BackgroundUrakami, K., Wada, K., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ishizu, H., Kashihara, K., Yamamoto, M., Tsuchiya-Ikemoto, K., et al. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00480-9 · Cited by 97 · cited 1×
“Tau fragments, including measures of total tau (t-tau) and phosphorylated tau (p-tau) have been more extensively studied in Alzheimer’s disease [130], but these tau species tend not to be reliably elevated in PSP [7, 131, 132].”
BackgroundWray, S., Saxton, M., Anderton, B. H., & Hanger, D. P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05321.x · Cited by 97
Cytokine expression and microglial activation in progressive supranuclear palsy
Fernández-Botrán, R., Ahmed, Z., Crespo, F. A., Gatenbee, C., Gonzalez, J., Dickson, D. W., & Litvan, I. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.007 · Cited by 93 · cited 1×
“cytokine, IL1β is seen in PSP affected brain regions and correlates with levels of microglial activation [88].”
BackgroundSelf-citationRepeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66
18 F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease
Nasrallah, I. M., Chen, Y. J., Hsieh, M.-K., Phillips, J. S., Ternes, K., Stockbower, G. E., Sheline, Y., McMillan, C. T., Grossman, M., & Wolk, D. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194282 · Cited by 60 · cited 1×
“18F-Flortaucipir (formerly AV-1451 and T807) is the most researched tau tracer to date and binds to paired helical filaments in 3R/4R tauopathies such as AD [119] and exhibits expected retention patterns in both amnestic AD [120, 121] and non-amnestic variants [122, 123].”
Background[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
Bevan Jones, W. R., Cope, T. E., Passamonti, L., Fryer, T. D., Hong, Y. T., Aigbirhio, F., Kril, J. J., Forrest, S. L., Allinson, K., Coles, J. P., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.366 · Cited by 44
Selenica, M.-L. B., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0152-0 · Cited by 40
Budur, K., West, T., Braunstein, J. B., Fogelman, I., Bordelon, Y. M., Litvan, I., Roberson, E. D., Hu, H., Verghese, P. B., Bateman, R. J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.07.241 · Cited by 12
Self-citation
Cited by
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
“Moreover, various tau related biomarkers have been explored more thoroughly in Alzheimer’s disease [127], while many nonAD tauopathies still don’t have commonly accepted tau related biomarkers [128, 129].”
BackgroundLiu, H., Huang, Z., Deng, B., Chang, Z., Yang, X., Guo, X., Yuan, F., Yang, Q., Wang, L., Zou, H., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0514 · Cited by 20
Seritan, A. L., Iosif, A.-M., Prakash, P., Wang, S. S., & Eisendrath, S. (2022) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-022-00261-7 · Cited by 16
“We decided to include patients with parkinsonism because of the high prevalence of anxiety and mood manifestations in atypical parkinsonian syndromes such as PSP and DLB (Bono et al., 2021; Coughlin & Litvan, 2020; Tampi et al., 2019).”
BackgroundStrobel, J., Müller, H.-P., Ludolph, A. C., Beer, A. J., Sollmann, N., & Kassubek, J. (2023) · Cells · doi:10.3390/cells12242776 · Cited by 10
“One major challenge is the complexity of PSP pathophysiology, which involves the accumulation of tau protein and degeneration of multiple brain regions [15,141].”
Background
Metadata
- Authors
- Coughlin, D. G., & Litvan, I.
- Venue
- Parkinsonism & Related Disorders
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 73
- Pages
- 105-116
- ISSN
- 1353-8020 (ISSN-L)
- OpenAlex
- W3029656577
- Cited by
- 110
- References
- 77
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.